Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05503511 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
A Phase 1 study, sponsored by NeuroPro Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT05503511 is a Phase 1 study that has completed, run by NeuroPro Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT05503511, a Phase 1 study, has completed, sponsored by NeuroPro Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
Interventions
- DRUG NPT 2042 (bumetanide analog) or Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05503511
The ClinicalTrials.gov registry entry for NCT05503511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroPro Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NPT 2042 (bumetanide analog) or Matching Placebo is the first listed.
NCT05503511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05503511 about?
NCT05503511 is a clinical study titled "Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects". Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
What is the current status of trial NCT05503511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-10-20. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT05503511?
The interventions under investigation include: NPT 2042 (bumetanide analog) or Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05503511?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.